Details of Disease

General Information of Disease (ID: DISUYOOU)

• Disease Name: Dyslipidemia
• Disease Class: 5C80-5C81: Dyslipidemia
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISUYOOU: Dyslipidemia
• ICD Code: ICD-11: ICD-11: 5C80-5C81
• Disease Identifiers:
  MONDO ID: MONDO_0015905
  MESH ID: D050171
  UMLS CUI: C5680608
  MedGen ID: 1826171
  Orphanet ID: 181437
  SNOMED CT ID: 370992007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABT-335	DM5NBIR	Approved	Small molecular drug	[1]
PITAVASTATIN CALCIUM	DM1UJO0	Approved	Small molecular drug	[2]
Saroglitazar	DMZANU5	Approved	NA	[3]

This Disease is Treated as An Indication in 11 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DCCR	DMRR5P0	Phase 3	NA	[4]
ARI-3037MO	DM9LNXS	Phase 2	NA	[5]
ARO-ANG3	DM3PDL8	Phase 2	RNA interference	[6]
PRC-4016	DMIPYUU	Phase 2	NA	[7]
SLx-4090	DMM3AI8	Phase 2	Small molecular drug	[8]
ZYH7	DMG7YI9	Phase 2	Small molecular drug	[9]
B7-2/GM-CSF	DM0LKHV	Phase 1	Small molecular drug	[10]
CER-002	DMLBKZV	Phase 1	NA	[11]
HPP-593	DMUA4XM	Phase 1	NA	[12]
SAR351034	DM15PG9	Phase 1	NA	[13]
TAP311	DM353WG	Phase 1	NA	[14]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CER-627	DMATXWH	Discontinued in Phase 1	NA	[15]
DS-1442	DMS4IBW	Discontinued in Phase 1	NA	[16]
R7232	DMETAP8	Discontinued in Phase 1	NA	[17]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Fibrates	DMFNTMY	Investigative	Small molecular drug	[18]
RG7232	DMSTL12	Investigative	NA	[19]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020 Dec 3;10(1):21117.
• [4] ClinicalTrials.gov (NCT01211847) Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT02250105) Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe ( 00 mg/dl) Hypertriglyceridemia. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04832971) A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia. U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT01972178) Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT01675154) Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT01539616) A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia. U.S. National Institutes of Health.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2639).
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028321)
• [12] ClinicalTrials.gov (NCT01524406) Safety Study of HPP593 in Subjects During and After Limb Immobilization. U.S. National Institutes of Health.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029833)
• [14] ClinicalTrials.gov (NCT01487460) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients. U.S. National Institutes of Health.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032323)
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036983)
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027351)
• [18] Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81.
• [19] Analysis of "On/Off" Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics. CPT Pharmacometrics Syst Pharmacol. 2015 Aug;4(8):465-73.
• [20] ClinicalTrials.gov (NCT01054508) Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers. U.S. National Institutes of Health.